Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
- 2014
Available online through MWHC library: 2006 - present
CONCLUSIONS: Combined obatoclax mesylate plus docetaxel is tolerable in patients with NSCLC, but response was minimal and neutropenia was a common adverse event. INTRODUCTION: The proapoptotic small-molecule pan-Bcl-2 inhibitor obatoclax mesylate (GX15-070) may enhance the cytotoxicity of chemotherapy in relapsed/refractory non-small-cell lung cancer (NSCLC). METHODS: Obatoclax was administered with docetaxel in patients with relapsed or refractory NSCLC- docetaxel as a 1-hour infusion on day 1 and obatoclax as a 24-hour infusion on days 1 and 2-every 3 weeks for up to eight cycles. Four dose levels were evaluated in phase 1 (level 1: docetaxel 55 mg/m x 1 and obatoclax 30 mg x 2; levels 2-4: docetaxel 75 mg/m and obatoclax 30 mg, 45 mg, or 60 mg x 2) to identify dose-limiting toxicity and a phase 2 dose. In phase 2, response and tolerability were evaluated. RESULTS: Eighteen patients were included in phase 1. Two dose-limiting toxicities occurred during cycle 1: one febrile neutropenia each at dose levels 3 and 4. Maximum tolerated dose was not reached; 32 patients (including 3 from phase 1) were treated in phase 2 with docetaxel 75 mg/m and obatoclax 60 mg (median 2 cycles). Three patients (11%) had partial responses in phase 2; two demonstrated stable disease lasting 12 weeks or more. Median duration of response was 4.8 months. Overall, median progression-free survival was 1.4 months. Neutropenia (31%), febrile neutropenia (16%), and dyspnea (19%) were the most common grade 3/4 adverse events observed.
English
1556-0864
*Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]
*Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy]
*Lung Neoplasms/dt [Drug Therapy]
*Neoplasm Recurrence, Local/dt [Drug Therapy]
Carcinoma, Non-Small-Cell Lung/mo [Mortality]
Humans
Lung Neoplasms/mo [Mortality]
Maximum Tolerated Dose
Neoplasm Recurrence, Local/mo [Mortality]
Pyrroles/ad [Administration & Dosage]
Pyrroles/ae [Adverse Effects]
Pyrroles/pk [Pharmacokinetics]
Taxoids/ad [Administration & Dosage]
Taxoids/ae [Adverse Effects]
Taxoids/pk [Pharmacokinetics]
MedStar Health Research Institute
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Available online through MWHC library: 2006 - present
CONCLUSIONS: Combined obatoclax mesylate plus docetaxel is tolerable in patients with NSCLC, but response was minimal and neutropenia was a common adverse event. INTRODUCTION: The proapoptotic small-molecule pan-Bcl-2 inhibitor obatoclax mesylate (GX15-070) may enhance the cytotoxicity of chemotherapy in relapsed/refractory non-small-cell lung cancer (NSCLC). METHODS: Obatoclax was administered with docetaxel in patients with relapsed or refractory NSCLC- docetaxel as a 1-hour infusion on day 1 and obatoclax as a 24-hour infusion on days 1 and 2-every 3 weeks for up to eight cycles. Four dose levels were evaluated in phase 1 (level 1: docetaxel 55 mg/m x 1 and obatoclax 30 mg x 2; levels 2-4: docetaxel 75 mg/m and obatoclax 30 mg, 45 mg, or 60 mg x 2) to identify dose-limiting toxicity and a phase 2 dose. In phase 2, response and tolerability were evaluated. RESULTS: Eighteen patients were included in phase 1. Two dose-limiting toxicities occurred during cycle 1: one febrile neutropenia each at dose levels 3 and 4. Maximum tolerated dose was not reached; 32 patients (including 3 from phase 1) were treated in phase 2 with docetaxel 75 mg/m and obatoclax 60 mg (median 2 cycles). Three patients (11%) had partial responses in phase 2; two demonstrated stable disease lasting 12 weeks or more. Median duration of response was 4.8 months. Overall, median progression-free survival was 1.4 months. Neutropenia (31%), febrile neutropenia (16%), and dyspnea (19%) were the most common grade 3/4 adverse events observed.
English
1556-0864
*Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]
*Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy]
*Lung Neoplasms/dt [Drug Therapy]
*Neoplasm Recurrence, Local/dt [Drug Therapy]
Carcinoma, Non-Small-Cell Lung/mo [Mortality]
Humans
Lung Neoplasms/mo [Mortality]
Maximum Tolerated Dose
Neoplasm Recurrence, Local/mo [Mortality]
Pyrroles/ad [Administration & Dosage]
Pyrroles/ae [Adverse Effects]
Pyrroles/pk [Pharmacokinetics]
Taxoids/ad [Administration & Dosage]
Taxoids/ae [Adverse Effects]
Taxoids/pk [Pharmacokinetics]
MedStar Health Research Institute
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't